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CC BY-NC-ND license (http://creativeAbstract Gemcitabine is the first-line treatment for pancreatic ductual adenocarcinoma
(PDAC) as well as acts against a wide range of other solid tumors. Patients usually have a good
initial response to gemcitabine-based chemotherapy but would eventually develop resistance.
To improve survival and prognosis of cancer patients, better understanding of the mechanisms
responsible for gemcitabine resistance and discovery of new therapeutic strategies are in great
need. Amounting evidence indicate that the developmental pathways, such as Hedgehog (Hh),
Wnt and Notch, become reactivated in gemcitabine-resistant cancer cells. Thus, the strategies
for targeting these pathways may sensitize cancer cells to gemcitabine treatment. In this re-
view, we will summarize recent development in this area of research and discuss strategies to
overcome gemcitabine resistance. Given the cross-talk between these three developmental
signaling pathways, designing clinical trials using a cocktail of inhibitory agents targeting all
these pathways may be more effective. Ultimately, our hope is that targeting these develop-
mental pathways may be an effective way to improve the gemcitabine treatment outcome in
cancer patients.
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Gemcitabine (20,20-difluoro-20-deoxycytidine; dFdC)1 is a
novel deoxycytidine analogue. Despite of some similarities
with other nucleoside analogues such as cytosine arabino-
side (AraC), gemcitabine has several unique properties and
specific spectrum of activity.2,3 The cytotoxic lesions
caused by gemcitabine include killing cells with active DNA
synthesis (S phase) and blocking cell cycle progression at
the G1/S phase boundary.4 Gemcitabine was originally
used for its antiviral effects but is now widely used as an
anti-cancer chemotherapeutic agent. Gemcitabine is rec-
ommended as a single agent for first-line chemotherapy for
patients with advanced pancreatic cancer.5 It is also used
for chemotherapy for patients with non-small cell lung
cancer,6 breast cancer,7 bladder cancer8 and ovarian
cancer.9
Patients usually have a good initial response to
gemcitabine-based chemotherapy but develop resistance
by time. Gemcitabine resistance can be either intrinsic or
acquired. Resistance can result from molecular and cellular
changes, including nucleotide metabolism enzymes, inac-
tivation of the apoptosis pathway, high expression of drug
efflux pumps, activation of the cancer stem cells or
epithelial-to-mesenchymal transition (EMT) pathway, up-
or down-regulated expression of microRNA (miRNA)
(Fig. 1). It has been demonstrated that pathways such as
Hedgehog (Hh), Wnt and Notch, which regulate embryonic
development and somatic stem cells (SCs), can be reac-
tivated in gemcitabine resistance cancer cells (Fig. 2).
Herein, we will describe recent advances towards targeting
these pathways with a goal to overcome gemcitabine
resistance.Fig. 1 A diagram of gemcitabine metabolism and proposed me
pro-drug that requires cellular uptake and serial phosphorylation t
DNA synthesis and then induce cancer cells apoptosis. Gemcitabine
result from molecular and cellular changes, including nucleotide m
teins, activation of the CSCs and EMT pathway.Gemcitabine metabolism and mechanism of
action
Gemcitabine is transported into cells by sodium-dependent
(concentrative nucleoside transporter hCNTs) and sodium-
independent (equilibrative nucleoside transporter hENTs)
mechanisms.10,11 Once inside the cell, gemcitabine un-
dergoes a series of phosphorylation by deoxycytidine kinase
(dCK) to the monophosphate (dFdCMP) and then by pyrim-
idine nucleoside monophosphate kinase (UMPeCMP kinase)
to give gemcitabine diphosphate (dFdCDP), resulting in
formation of gemcitabine triphosphate (dFdCTP) mediated
by nucleoside diphosphate kinase (NDPK).12 The first phos-
phorylation by dCK is considered the rate-limiting step for
dFdCDP and dFdCTP production.
Gemcitabine can get inactivated through deamination by
cytidine deaminase (CDA), and when in the monophosphate
form by deoxycytidylate deaminase (dCTD). Gemcitabine
may also become inactivated by dephosphorylation of the
monophosphate formby50-nucleotidases (50-NTs), converting
nucleotides back to nucleosides. On the other hand, gemci-
tabine exhibits a unique property called self-potentiation to
enhance its activation. The diphosphate form (dFdCDP) in-
hibits ribonucleotide reductase M1 or M2 (RRM1/RRM2) that
convert CDP to dCDP, leading to depletion of dCTP pools and
facilitating incorporation of dFdCTP into DNA.13Known mechanisms of gemcitabine resistance
One mechanism responsible for gemcitabine resistance is
the dysregulation of the proteins participating in gemcita-
bine metabolism pathways, including deficiency of hENT1,chanisms of gemcitabine resistance. Gemcitabine (dFdC) is a
o become pharmacologically active. Gemcitabine can interrupt
resistance can be either intrinsic or acquired. Resistance can
etabolism enzymes, apoptosis pathway, ABC transporter pro-
Fig. 2 Diagrams of the Hedgehog, Wnt, Notch pathways and their roles for gemcitabine resistance. Hedgehog (Hh), Wnt and
Notch signaling, which regulate embryonic development and somatic stem cells, may be reactivated in gemcitabine-resistant
cancer cells. Elevated expression of the target genes in these pathways may result in inactivation of the apoptosis pathway, high
expression of drug efflux pumps or activation of the cancer stem cells (CSCs), ultimately leading to gemcitabine resistance.
Gemcitabine resistance in cancer 301down-regulation of rate-limiting enzyme dCK, and up-
regulation of RRM1/RRM2.14,15 Hu antigen R (HuR), which
is an RNA-binding protein that post-transcriptionally regu-
lates dCK, is also associated with gemcitabine efficacy.
High levels of HuR correlated with a better overall survival
in gemcitabine-treated patients.16
Another gemcitabine resistance mechanism is high
expression of drug efflux pumps, such as (ABC) transporter
family proteins.17 These proteins are highly expressed in
cancer stemcells (CSCs) and havebeen shown to protect CSCs
from chemotherapeutic agents.18 Recent evidence has sup-
ported the link of gemcitabine resistance and EMTwith stem
cell phenotype.19 In general, therapeutics directed against
CSCs and EMT offer new strategies to chemoresistance.
Gemcitabine resistance is also associated with multiple
genetic and epigenetic abnormalities. Changes in one or a
few genes remain crucial for maintaining drug resistance
cell survival and malignant phenotype. There is evidence to
indicate that NF-kB,20e23 AKT,20,24,25 MAPK,25,26 HIF-
1a27pathways are involved in gemcitabine resistance
in vitro and some in vivo models (Fig. 1). However, the
functional significance of these molecules for gemcitabine
resistance remains largely untested.Relevance of hedgehog signaling to
gemcitabine resistance
As an essential developmental signaling pathway, the Hh
pathway is critical for maintaining tissue polarity andstem cell population. Hedgehog signaling molecules in
mammal include three ligands (Sonic hedgehog-Shh, In-
dian hedgehog-Ihh and Desert hedgehog-Dhh), two re-
ceptors (Patched1-Ptc1, Patched2-Ptc2), a key signal
transducer smoothened (Smo) and three transcription
factors (Gli1, Gli2, Gli3). When ligands are not present,
Smo function is inhibited by another transmembrane
protein (Ptc1, Ptc2). Upon binding of an active Hh ligand,
this inhibitory effect is lifted, allowing Smo to signal
downstream, eventually leading to active transcription of
Gli molecules through binding the specific consensus se-
quences located in the promoter region of target
genes.28,29 Besides these canonical Hh pathways, there
are non-canonical Hh pathways activated directly through
Ptc1 or Smo, or other pathways including the PI3K/AKT
and MEK signaling cascades.30 Dysregulated signaling
through the Hh pathway is implicated in virtually all
human cancers. Furthermore, Hh pathway is now also
recognized as a major driver of resistance to a number of
chemotherapeutical reagents. Smo inhibitors, including
vismodegib (GDC-0449), sonidegib (LDE225), BMS-833923,
PF-04449913, and LY2940680, are being tested in a range
of advanced cancers (NCI Clinical Trail Database (http://
www.clinicaltrials.gov/)). To our disappointment, how-
ever, the Smo inhibitors seem to be ineffective in most
extracutaneous solid tumors.31 Therefore, Smo inhibition
alone may not provide sufficient efficacy in these cancers,
and combinations with other conventional cytotoxic anti-
tumor agents might be needed to achieve maximal
benefit. Currently, several Phase II trials of hedgehog
302 Y. Jia, J. Xiepathway inhibitor vismodegib and Phase I trials of LDE225
in combination with gemcitabine are ongoing (http://
www.clinicaltrials.gov/).
Activation of Hh signaling may not work alone because
cross-talk with other signaling pathways plays critical roles
in gemcitabine resistance. For example, MAP3K10 over-
expression can result in up-regulation of Gli1 and Gli2,
leading to decrease in the gemcitabine sensitivity of in
pancreatic cancer cells.32 Perifosine, a novel Akt inhibitor,
through suppressing Gli1 activation, can enhance
gemcitabine-induced cytotoxicity in pancreatic cancer
cells.33 Lithium synergistically enhances the anti-cancer
effect of gemcitabine, by inhibiting the activity of
glycogen synthase kinase 3b (GSK3b), therefore promoting
the ubiquitin-dependent proteasome degradation of Gli1.34
ABCB2, the drug efflux transporters, serves as the down-
stream target of Shh signaling, and its expression can in-
crease gemcitabine resistance in PDAC cells.35
Understanding how integration of HH signaling with other
pathways and discovery and synthesis of Gli specific in-
hibitors is in great need for effective suppression of non-
canonical Hh signaling in cancer.
Recent reports have also indicated that hedgehog
signaling may be critical for maintaining a small cell popu-
lation with stem cell properties, and thus conferring resis-
tance to chemotherapy. There is evidence to indicate thatHh
signaling regulates expression of several cancer stem cell-
relatedmarkers, such as ALDH1, Bmi1, Snail, Wnt2, PDGFRa,
Jagged-1, CD44 and c-MET.36e42 The level of Hh expression is
often higher in the cancer stem cell population.43e46 Thus,
wehave reasons to believe that inhibition ofHh signalingmay
be effective in reducing the number of cancer stem cells,
which may play an important role for chemotherapy and
radiotherapy resistance. Chloroquine treatment in combi-
nation with gemcitabine significantly decreased CSCs, via
inhibition of hedgehog signaling in the stroma, which sup-
ports CSCs and non-CSCs via a paracrine mechanism.47
Arsenictrioxide (ATO) is described as a SHH inhibitor. Com-
bination treatment of ATO and low dose gemcitabine inhibits
tumor growth, decreases the expression of CD24, CD44, and
aldehyde dehydrogenase 1 family member A1 significantly in
mouse model.48 In response to gemcitabine, both Shh and
CSCs markers as well as EMT regulators are over-expressed,
indicating a protective role of hedgehog signaling against
chemotherapeutic drugs.19 Discovery of a more specific and
complete set of cell surface markers may help to further
characterize CSCs, and the role that Hh pathway played in
drug resistance and the in-depth mechanism require further
systemic studies.The role of Wnt signaling for gemcitabine
resistance
The Wnt signaling pathway controls and regulates crucial
aspects of development, cell proliferation, survival and
polarity.49 Wnts are a family of 19 secreted glycoproteins,
binding to a number of 7-transmembrane receptors of the
Frizzled (FZD) family.50 These receptors transduce signal to
several intracellular proteins, such as Dishevelled (Dsh),
glycogen synthase kinase-3b (GSK-3), Axin, Adenomatous
Polyposis Coli (APC), and b-Catenin. To date, majorsignaling branches have been identified including the ca-
nonical Wnt/b-Catenin pathway, the non-canonical planar
cell polarity pathway, and the non-canonical Wnt/calcium
pathway. These pathways are being actively dissected at
the molecular and biochemical levels. When FZD co-
operates with LRP5/6 (low-density lipoprotein receptor-
related proteins 5 and 6), the canonical Wnt/b-Catenin
signaling pathway is activated.51 In the absence of the
activating Wnt signals, b-Catenin is phosphorylated by a
complex of GSK-3b, proteins APC, b-TRCP and Axin. Non-
canonical Wnt signaling can phosphorylate small G-pro-
teins and JNK to transmit the signal to the nucleus, or
release calcium affecting Nemo-like kinase (NLK) or nuclear
factor of activated T-cells (NFAT).52
Emerging evidence indicates that activation of the Wnt
pathway is involved in cancer development and drug
resistance. Wnt/b-Catenin signaling is activated in gemci-
tabine-resistant lung cancer cell lines.53 WNT5A expression
leads to resistance to gemcitabine-induced apoptosis in a
xenograft model of pancreatic ductal adenocarcinoma
(PDAC).54 The heparan sulfate mimetic PG545 in combina-
tion with gemcitabine exerts anti-tumor activity by dis-
rupting Wnt/b-Catenin signaling.55 Masitinib, a tyrosine
kinase inhibitor, can sensitize gemcitabine treatment
through down-regulation of the Wnt/b-Catenin signaling
pathway in pancreatic cancer cell lines, which is further
confirmed in a Phase II clinical study.56 These therapeutic
approaches to target upstream or downstream of Wnt
signaling pathway indicate that combination therapy may
be required to effectively treat gemcitabine-resistant
malignancies.
Recent reports have implicated Wnt pathway may be
especially important in maintaining the subpopulation of
cancer cells with stem cell properties as well as conferring
resistance to chemotherapies. Wnt signaling is increased in
pancreatic cancer side population (SP) cells. Furthermore,
when cultured with increasing concentrations of gemcita-
bine, the proportion of SP cells were significantly
enriched.57 EMT has been implicated as a drug resistance
mechanism, allowing tumor cells to escape from cytotoxic
and pathway targeted therapies. Activation of Wnt
signaling up-regulates the EMT activator ZEB1 and de-
termines response to gemcitabine in mantle cell lym-
phoma.58 It will be important for future research to unravel
the interconnectedness of Wnt pathway with CSCs and EMT
in gemcitabine resistance.The Notch pathway regulates cancer stem cells
in gemcitabine resistance
It has been well known that Notch signaling plays important
roles for regulating cellecell communication, cell prolif-
eration, differentiation and apoptosis. Activation of Notch
receptors (Notch-1e4) is often achieved by canonical li-
gands, Delta-like ligands (DLLs) 1, 3 and 4, and Jagged li-
gands 1 and 2. The binding of ligandereceptor results in g-
secretase-mediated cleavage and nuclear localization of its
intracellular domain to regulate notch-specific gene
expression.59
Evidence suggests that Notch signaling may play a crucial
role in the tumor progression and possibly therapy-
Gemcitabine resistance in cancer 303resistance.60,61 Notch-2 and Jagged-1 are highly up-
regulated in gemcitabine-resistant pancreatic cancer
cells.62 Notch-3 mRNA expression is predicted to be the key
predictive biomarker for gemcitabine effect and sensitivity
in pre-treatment endoscopic ultrasound-guided fine-needle
aspiration (EUS-FNA) samples from patients with PDC.63
Inhibition of Notch-1 by siRNA enhances the sensitivity to
gemcitabine in pancreatic cancer through activating
apoptosis activity.64 Midkine (MK)eNotch-2 interaction in-
creases Notch signaling, elevates EMT, and is associated
with gemcitabine resistance.65 Moreover, inhibition of
Notch-3 enhances the sensitivity to gemcitabine in
pancreatic cancer through inactivation of the PI3K/Akt-
dependent pathway.66 The g-secretase inhibitors DAPT
and MRK003 effectively inhibit intra-tumoral Notch
signaling in PDA, leading to a remarkable increase in che-
mosensitivity to gemcitabine.67,68
Emerging evidence clearly shows that abnormal Notch
signaling may contribute to carcinogenesis by deregulating
the self-renewal of normal stem cells. Inappropriate acti-
vation of Notch signaling could be an early event leading to
accumulation of undifferentiated precursor cells in
pancreatic cancers.69 MRK-003, g-secretase inhibitor,
treatment results in down-regulation of nuclear Notch-1
intracellular domain, and a decrease in tumor-initiating
cells that are capable of extensive self-renewal.70
Furthermore, the proportion of CD24þCD44þ CSCs in
pancreatic cancer cells line increased after gemcitabine
treatment and this increase was mediated by the Notch
pathway.71 A Notch signaling pathway inhibitor (L1790) and
Hes-1 siRNA are shown to reverse the chemoresistance
induced by PSCs.72 Neutralizing antibodies against human
DLL4 reduces the percentage of CSC in gemcitabine-
resistant mouse model.73 Through down-regulation ofTable 1 Summary of combination therapies and their mechanis
Pathway Target Compound Mechanism of action
Hh Smo Vismodegib,
LDE225
Phase II trials of vismodegib a
are ongoing (http://www.clin
Chloroquine Chloroquine treatment in com
inhibition of hedgehog signal
Gli1 Perifosine Perifosine, an Akt inhibitor, t
induced cytotoxicity in pancr
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PG545 PG545 in combination with g
Catenin signaling.55
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Through down-regulation of N
selection of ALDH1 positive cNotch-1, Sulforaphane (SF) prevented gemcitabine-induced
selection of ALDH-positive cells.74 As indicated above,
Notch signaling may be a promising target to overcome
gemcitabine resistance.
Cross-talk among signaling pathways
Cross-talks among Hh, Notch or Wnt signaling pathways
have been reported in a variety of cancer cells. The tran-
scription of Jagged-2, a Notch ligand, can be up-regulated
in response to Hh pathway activation.75 Whereas Wnt/b-
Catenin can activate Jagged-1,76 Wnt-1 induces trans-
formation and tumorigenesis in human mammary epithelial
cells, through up-regulation of Notch pathway. Notch and
Hh signaling both can activate Hes-1.77 On the other hand,
Hh signaling is found to inhibit Wnt signaling via up-
regulation of Wnt-inhibitory factor sFRP1, and to suppress
b-Catenin transcriptional activity.78 CK1 and GSK3, the core
component of the Wnt pathway, regulate Gli1 proteolytic
processing.79 Therefore, combination therapies targeting
more than one pathway in cancer may be more effective.
Hh may modulate the tumorigenic property in cooperation
with Notch in breast cancer. Phase I and Phase Ib/II trials,
combining Hh pathway inhibitor vismodegib and Notch
pathway inhibitor RO4929097 are being conducted in pa-
tients with breast cancer and sarcoma (http://www.
clinicaltrials.gov).
Conclusions and future directions
Gemcitabine still has clinical potential to treat a broad
spectrum of human cancers, but resistance is probably the
major impediment to achieve satisfactory clinicalm in regulation gemcitabine resistance.
nd Phase I trials of LDE225 in combination with gemcitabine
icaltrials.gov/).
bination with gemcitabine significantly decreased CSCs, via
ing in the stroma.47
hrough suppressing Gli1 activation, can enhance gemcitabine-
eatic cancer cells33
lycogen synthase kinase 3b (GSK3b), therefore promoting the
me degradation of Gli1.34
O and low dose gemcitabine inhibits tumor growth, decreases
, and aldehyde dehydrogenase 1 family member A1
48
emcitabine exerts anti-tumor activity by disrupting Wnt/b-
hibitor, can sensitize gemcitabine treatment through down-
naling pathway.56
inhibit intratumoral Notch signaling in PDA, leading to a
osensitivity to gemcitabine67,68
he gemcitabine resistance induced by PSCs.72
st human DLL4 reduces the percentage of CSC in gemcitabine-
otch-1, Sulforaphane (SF) prevented gemcitabine-induced
ells74
304 Y. Jia, J. Xieoutcomes. As evident in the numerous studies, targeting
developmental pathways is quite promising to improve
gemcitabine efficacy in cancer (Table 1).
There are a number of challenges in overcoming gem-
citabine resistance. First, the mechanism of gemcitabine
resistance is still largely unknown. Inhibition of a single
signaling pathway is unlikely to result in a substantial
improvement in gemcitabine resistance, owing to the cross-
talk from various pathways. Second, despite exciting data
in various tumor and their disease models, it is still too
early to know whether any of these therapeutic agents that
specifically target the developmental pathway will be
efficacious with an acceptable safety profile. Third, further
studies are urgently needed to confirm the relevance of
these developmental signaling pathways to gemcitabine
resistance and to find reasonable combination for therapy.
Despite these future challenges, targeting Hh, Notch and
Wnt signaling pathways to improve the gemcitabine treat-
ment outcome in cancer patients is clearly the way for
future studies.
Conflicts of interest
The authors declare no conflicts of interest.
Acknowledgments
Current research in my laboratory is supported by grants from
the National Cancer Institute CA155086, Riley Children’s
Foundation,Wells Center for Pediatric Research and Shandong
Provincial Natural Science Foundation of China ZR2015HM018.
Due to space limit, we could not include many important
findings in this review but want to take this opportunity to
thank all the investigators in this field for their works.
References
1. Bianchi V, Borella S, Calderazzo F, Ferraro P, Chieco Bianchi L,
Reichard P. Inhibition of ribonucleotide reductase by 2’-
substituted deoxycytidine analogs: possible application in AIDS
treatment. Proc Natl Acad Sci U. S. A. 1994;91:8403e8407.
2. Gandhi V, Plunkett W. Modulatory activity of 2’,2’-difluor-
odeoxycytidine on the phosphorylation and cytotoxicity of
arabinosyl nucleosides. Cancer Res. 1990;50:3675e3680.
3. Hertel LW, Boder GB, Kroin JS, et al. Evaluation of the anti-
tumor activity of gemcitabine (20,20-difluoro-20-deoxycytidine).
Cancer Res. 1990;50:4417e4422.
4. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action
of 2’,2’-difluorodeoxycytidine on DNA synthesis. Cancer Res.
1991;51:6110e6117.
5. Burris 3rd HA, Moore MJ, Andersen J, et al. Improvements in
survival and clinical benefit with gemcitabine as first-line
therapy for patients with advanced pancreas cancer: a ran-
domized trial. J Clin Oncol e Off J Am Soc Clin Oncol. 1997;15:
2403e2413.
6. Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of
gemcitabine plus cisplatin versus cisplatin alone in patients
with locally advanced or metastatic non-small-cell lung cancer.
J Clin Oncol e Off J Am Soc Clin Oncol. 2000;18:122e130.
7. Nagourney RA, Flam M, Link J, et al. Carboplatin plus gemci-
tabine repeating doublet therapy in recurrent breast cancer.
Clin Breast Cancer. 2008;8:432e435.8. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine
and cisplatin versus methotrexate, vinblastine, doxorubicin,
and cisplatin in advanced or metastatic bladder cancer: results
of a large, randomized, multinational, multicenter, phase III
study. J Clin Oncol. 2000;18:3068e3077.
9. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus car-
boplatin compared with carboplatin in patients with platinum-
sensitive recurrent ovarian cancer: an intergroup trial of the
AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol.
2006;24:4699e4707.
10. Rauchwerger DR, Firby PS, Hedley DW, Moore MJ. Equili-
brative-sensitive nucleoside transporter and its role in gemci-
tabine sensitivity. Cancer Res. 2000;60:6075e6079.
11. Spratlin J, Sangha R, Glubrecht D, et al. The absence of human
equilibrative nucleoside transporter 1 is associated with reduced
survival in patients with gemcitabine-treated pancreas adeno-
carcinoma. Clin Cancer Res. 2004;10:6956e6961.
12. Mini E, Nobili S, Caciagli B, Landini I, Mazzei T. Cellular phar-
macology of gemcitabine. Ann Oncol. 2006;17:v7e12.
13. Heinemann V, Xu YZ, Chubb S, et al. Cellular elimination of
20,20-difluorodeoxycytidine 50-triphosphate: a mechanism of
self-potentiation. Cancer Res. 1992;52:533e539.
14. Zhou BS, Tsai P, Ker R, et al. Overexpression of transfected
human ribonucleotide reductase M2 subunit in human cancer
cells enhances their invasive potential. Clin Exp Metastasis.
1998;16:43e49.
15. Zhou J, Oliveira P, Li X, Chen Z, Bepler G. Modulation of the
ribonucleotide reductase-antimetabolite drug interaction in
cancer cell lines. J Nucleic Acids. 2010;2010:597098.
16. Costantino CL, Witkiewicz AK, Kuwano Y, et al. The role of HuR
in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates
the expression of the gemcitabine metabolizing enzyme
deoxycytidine kinase. Cancer Res. 2009;69:4567e4572.
17. Chen M, Xue X, Wang F, et al. Expression and promoter
methylation analysis of ATP-binding cassette genes in pancre-
atic cancer. Oncol Rep. 2012;27:265e269.
18. Zinzi L, Contino M, Cantore M, Capparelli E, Leopoldo M,
Colabufo NA. ABC transporters in CSCs membranes as a novel
target for treating tumor relapse. Front Pharmacol. 2014;5:163.
19. Quint K, Tonigold M, Di Fazio P, et al. Pancreatic cancer cells
surviving gemcitabine treatment express markers of stem cell
differentiation and epithelial-mesenchymal transition. Int J
Oncol. 2012;41:2093e2102.
20. Arlt A, Gehrz A, Muerkoster S, et al. Role of NF-kappaB and
Akt/PI3K in the resistance of pancreatic carcinoma cell lines
against gemcitabine-induced cell death. Oncogene. 2003;22:
3243e3251.
21. Pan X, Arumugam T, Yamamoto T, et al. Nuclear factor-kappaB
p65/relA silencing induces apoptosis and increases gemcita-
bine effectiveness in a subset of pancreatic cancer cells. Clin
Cancer Res e Off J Am Assoc Cancer Res. 2008;14:8143e8151.
22. Jung H, Kim JS, Kim WK, et al. Intracellular annexin A2 regu-
lates NF-kappaB signaling by binding to the p50 subunit: im-
plications for gemcitabine resistance in pancreatic cancer. Cell
Death Dis. 2015;6:e1606.
23. Yu Y, Wang J, Xia N, Li B, Jiang X. Maslinic acid potentiates the
antitumor activities of gemcitabine in vitro and in vivo by
inhibiting NF-kappaB-mediated survival signaling pathways in
human gallbladder cancer cells. Oncol Rep. 2015;33:
1683e1690.
24. Simon Jr PO, McDunn JE, Kashiwagi H, et al. Targeting AKTwith
the proapoptotic peptide, TAT-CTMP: a novel strategy for the
treatment of human pancreatic adenocarcinoma. Int J Cancer
J. 2009;125:942e951.
25. Trehoux S, Duchene B, Jonckheere N, Van Seuningen I. The
MUC1 oncomucin regulates pancreatic cancer cell biological
properties and chemoresistance. Implication of p42-44 MAPK,
Gemcitabine resistance in cancer 305Akt, Bcl-2 and MMP13 pathways. Biochem Biophysical Res
Commun. 2015;456:757e762.
26. Yang XL, Lin FJ, Guo YJ, Shao ZM, Ou ZL. Gemcitabine resis-
tance in breast cancer cells regulated by PI3K/AKT-mediated
cellular proliferation exerts negative feedback via the MEK/-
MAPK and mTOR pathways. Onco Targets Ther. 2014;7:
1033e1042.
27. Wang R, Cheng L, Xia J, Wang Z, Wu Q, Wang Z. Gemcitabine
resistance is associated with epithelial-mesenchymal transi-
tion and induction of HIF-1alpha in pancreatic cancer cells.
Curr Cancer Drug Targets. 2014;14:407e417.
28. Kinzler KW, Vogelstein B. The GLI gene encodes a nuclear
protein which binds specific sequences in the human genome.
Mol Cell Biol. 1990;10:634e642.
29. Sasaki H, Hui C, Nakafuku M, Kondoh H. A binding site for Gli
proteins is essential for HNF-3beta floor plate enhancer ac-
tivity in transgenics and can respond to Shh in vitro. Develop-
ment. 1997;124:1313e1322.
30. Jenkins D. Hedgehog signalling: emerging evidence for non-
canonical pathways. Cell Signal. 2009;21:1023e1034.
31. LoRusso PM, Rudin CM, Reddy JC, et al. Phase I trial of
hedgehog pathway inhibitor vismodegib (GDC-0449) in patients
with refractory, locally advanced or metastatic solid tumors.
Clin Cancer Res e Off J Am Assoc Cancer Res. 2011;17:
2502e2511.
32. An Y, Cai B, Chen J, et al. MAP3K10 promotes the proliferation
and decreases the sensitivity of pancreatic cancer cells to
gemcitabine by upregulating Gli-1 and Gli-2. Cancer Lett.
2013;329:228e235.
33. Xin Y, Shen XD, Cheng L, Hong DF, Chen B. Perifosine inhibits
S6K1-Gli1 signaling and enhances gemcitabine-induced anti-
pancreatic cancer efficiency. Cancer Chemother Pharmacol.
2014;73:711e719.
34. Peng Z, Ji Z, Mei F, Lu M, Ou Y, Cheng X. Lithium inhibits
tumorigenic potential of PDA cells through targeting hedgehog-
GLI signaling pathway. PLoS One. 2013;8:e61457.
35. Xu M, Li L, Liu Z, et al. ABCB2 (TAP1) as the downstream target
of SHH signaling enhances pancreatic ductal adenocarcinoma
drug resistance. Cancer Lett. 2013;333:152e158.
36. Gu D, Liu H, Su GH, et al. Combining hedgehog signaling inhi-
bition with focal irradiation on reduction of pancreatic cancer
metastasis. Mol Cancer Ther. 2013;12:1038e1048.
37. Inaguma S, Kasai K, Hashimoto M, Ikeda H. GLI1 modulates EMT
in pancreatic cancereletter. Cancer Res. 2012;72:3702e3703
[author reply 3704e3705].
38. Liu S, Dontu G, Mantle ID, et al. Hedgehog signaling and Bmi-1
regulate self-renewal of normal and malignant human mam-
mary stem cells. Cancer Res. 2006;66:6063e6071.
39. Song Z, Yue W, Wei B, et al. Sonic hedgehog pathway is
essential for maintenance of cancer stem-like cells in human
gastric cancer. PLoS One. 2011;6:e17687.
40. Takebe N, Harris PJ, Warren RQ, Ivy SP. Targeting cancer stem
cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat
Rev Clin Oncol. 2011;8:97e106.
41. Tanaka H, Nakamura M, Kameda C, et al. The Hedgehog
signaling pathway plays an essential role in maintaining the
CD44þCD24-/low subpopulation and the side population of
breast cancer cells. Anticancer Res. 2009;29:2147e2157.
42. Takahashi T, Kawakami K, Mishima S, et al. Cyclopamine in-
duces eosinophilic differentiation and upregulates CD44
expression in myeloid leukemia cells. Leukemia Res. 2011;35:
638e645.
43. Bar EE, Chaudhry A, Lin A, et al. Cyclopamine-mediated
hedgehog pathway inhibition depletes stem-like cancer cells in
glioblastoma. Stem Cells. 2007;25:2524e2533.
44. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic
cancer stem cells. Cancer Res. 2007;67:1030e1037.45. Visbal AP, LaMarca HL, Villanueva H, et al. Altered differenti-
ation and paracrine stimulation of mammary epithelial cell
proliferation by conditionally activated Smoothened. Dev Biol.
2011;352:116e127.
46. Su W, Meng F, Huang L, Zheng M, Liu W, Sun H. Sonic hedgehog
maintains survival and growth of chronic myeloid leukemia
progenitor cells through beta-catenin signaling. Exp Hematol.
2012;40:418e427.
47. Balic A, Sorensen MD, Trabulo SM, et al. Chloroquine targets
pancreatic cancer stem cells via inhibition of CXCR4 and
hedgehog signaling. Mol Cancer Ther. 2014;13:1758e1771.
48. Han JB, Sang F, Chang JJ, et al. Arsenic trioxide inhibits
viability of pancreatic cancer stem cells in culture and in a
xenograft model via binding to SHH-Gli. Onco Targets Ther.
2013;6:1129e1138.
49. Logan CY, Nusse R. The Wnt signaling pathway in development
and disease. Annu Rev Cell Dev Biol. 2004;20:781e810.
50. Niehrs C. The complex world of WNT receptor signalling. Nat
Rev Mol Cell Biol. 2012;13:767e779.
51. Veeman MT, Axelrod JD, Moon RT. A second canon. Functions
and mechanisms of beta-catenin-independent Wnt signaling.
Dev Cell. 2003;5:367e377.
52. Janikova M, Skarda J. Differentiation pathways in carcinogen-
esis and in chemo- and radioresistance. Neoplasma. 2012;59:
6e17.
53. Zhang HH, Zhang ZY, Che CL, Mei YF, Shi YZ. Array analysis for
potential biomarker of gemcitabine identification in non-small
cell lung cancer cell lines. Int J Clin Exp Pathology. 2013;6:
1734e1746.
54. Griesmann H, Ripka S, Pralle M, et al. WNT5A-NFAT signaling
mediates resistance to apoptosis in pancreatic cancer.
Neoplasia. 2013;15:11e22.
55. Jung DB, Yun M, Kim EO, et al. The heparan sulfate mimetic
PG545 interferes with Wnt/beta-catenin signaling and signifi-
cantly suppresses pancreatic tumorigenesis alone and in com-
bination with gemcitabine. Oncotarget. 2015;6:4992e5004.
56. Humbert M, Casteran N, Letard S, et al. Masitinib combined
with standard gemcitabine chemotherapy: in vitro and in vivo
studies in human pancreatic tumour cell lines and ectopic
mouse model. PLoS One. 2010;5:e9430.
57. Niess H, Camaj P, Renner A, et al. Side population cells of
pancreatic cancer show characteristics of cancer stem cells
responsible for resistance and metastasis. Target Oncol. 2015;
10:215e227.
58. Sanchez-Tillo E, Fanlo L, Siles L, et al. The EMT activator ZEB1
promotes tumor growth and determines differential response
to chemotherapy in mantle cell lymphoma. Cell Death Differ.
2014;21:247e257.
59. Fiuza UM, Arias AM. Cell and molecular biology of Notch. J
Endocrinol. 2007;194:459e474.
60. Meng RD, Shelton CC, Li YM, et al. gamma-Secretase inhibitors
abrogate oxaliplatin-induced activation of the Notch-1
signaling pathway in colon cancer cells resulting in enhanced
chemosensitivity. Cancer Res. 2009;69:573e582.
61. Wang Z, Li Y, Ahmad A, et al. Targeting Notch signaling
pathway to overcome drug resistance for cancer therapy.
Biochimica Biophysica Acta. 2010;1806:258e267.
62. Wang Z, Li Y, Kong D, et al. Acquisition of epithelial-
mesenchymal transition phenotype of gemcitabine-resistant
pancreatic cancer cells is linked with activation of the notch
signaling pathway. Cancer Res. 2009;69:2400e2407.
63. Eto K, Kawakami H, Kuwatani M, et al. Human equilibrative
nucleoside transporter 1 and Notch3 can predict gemcitabine
effects in patients with unresectable pancreatic cancer. Br J
Cancer. 2013;108:1488e1494.
64. Du X, Wang YH, Wang ZQ, et al. Down-regulation of Notch1 by
small interfering RNA enhances chemosensitivity to
306 Y. Jia, J. Xiegemcitabine in pancreatic cancer cells through activating
apoptosis activity. J Zhejiang Univ Med Sci. 2014;43:313e318.
65. Gungor C, Zander H, Effenberger KE, et al. Notch signaling
activated by replication stress-induced expression of midkine
drives epithelial-mesenchymal transition and chemoresistance
in pancreatic cancer. Cancer Res. 2011;71:5009e5019.
66. Yao J, Qian C. Inhibition of Notch3 enhances sensitivity to
gemcitabine in pancreatic cancer through an inactivation of
PI3K/Akt-dependent pathway. Med Oncol. 2010;27:1017e1022.
67. Cook N, Frese KK, Bapiro TE, et al. Gamma secretase inhibition
promotes hypoxic necrosis in mouse pancreatic ductal adeno-
carcinoma. J Exp Med. 2012;209:437e444.
68. Du X, Zhao YP, Zhang TP, et al. Alteration of the intrinsic
apoptosis pathway is involved in Notch-induced chemo-
resistance to gemcitabine in pancreatic cancer. Archives Med
Res. 2014;45:15e20.
69. Lomberk G, Urrutia R. Primers on molecular pathwaysenotch.
Pancreatol e Off J Int Assoc Pancreatol. 2008;8:103e104.
70. Mizuma M, Rasheed ZA, Yabuuchi S, et al. The gamma secre-
tase inhibitor MRK-003 attenuates pancreatic cancer growth in
preclinical models. Mol Cancer Ther. 2012;11:1999e2009.
71. Lee JY, Song SY, Park JY. Notch pathway activation is associ-
ated with pancreatic cancer treatment failure. Pancreatology.
2014;14:48e53.
72. Cao F, Li J, Sun H, Liu S, Cui Y, Li F. HES 1 is essential for
chemoresistance induced by stellate cells and is associatedwith poor prognosis in pancreatic cancer. Oncol Rep. 2015;33:
1883e1889.
73. Yen WC, Fischer MM, Hynes M, et al. Anti-DLL4 has broad
spectrum activity in pancreatic cancer dependent on targeting
DLL4-Notch signaling in both tumor and vasculature cells. Clin
Cancer Res. 2012;18:5374e5386.
74. Kallifatidis G, Labsch S, Rausch V, et al. Sulforaphane increases
drug-mediated cytotoxicity toward cancer stem-like cells of
pancreas and prostate. Mol Ther. 2011;19:188e195.
75. Rabadan MA, Cayuso J, Le Dreau G, et al. Jagged2 controls the
generation of motor neuron and oligodendrocyte progenitors in
the ventral spinal cord. Cell Death Differ. 2012;19:209e219.
76. Chen X, Stoeck A, Lee SJ, Shih Ie M, Wang MM,Wang TL. Jagged1
expression regulated by Notch3 and Wnt/beta-catenin signaling
pathways in ovarian cancer. Oncotarget. 2010;1:210e218.
77. Schreck KC, Taylor P, Marchionni L, et al. The Notch target
Hes1 directly modulates Gli1 expression and Hedgehog
signaling: a potential mechanism of therapeutic resistance.
Clin Cancer Res. 2010;16:6060e6070.
78. He J, Sheng T, Stelter AA, et al. Suppressing Wnt signaling by
the hedgehog pathway through sFRP-1. J Biol Chem. 2006;281:
35598e35602.
79. Ramaswamy B, Lu Y, Teng KY, et al. Hedgehog signaling is a
novel therapeutic target in tamoxifen-resistant breast cancer
aberrantly activated by PI3K/AKT pathway. Cancer Res. 2012;
72:5048e5059.
